https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/next-five-years-ground-breaking-research/
The next five years of ground-breaking research
3 Apr 2017, 12:23 p.m.
The NIHR Great Ormond Street Biomedical Research Centre (BRC) starts a new five-year funding term today.
In September 2016 the NIHR announced the £37 million award to GOSH BRC which will underpin translational research at Great Ormond Street Hospital (GOSH) and allow us to continue bringing the scientific discoveries made in laboratories into ‘first in child’ clinical trials. The GOSH BRC is one of 20 NIHR BRCs across the UK, and the only such centre specifically focusing on research into children’s medicine.
Professor Thomas Voit, Director of the NIHR GOSH BRC discussed his vision for the centre: “We want to be at the forefront of early development of medicines and bringing those to the children that need them. This £37million investment in infrastructure and people will help us achieve this.”
Funding research at GOSH
Funding allows the NIHR GOSH BRC to support vital research facilities at GOSH and the UCL Great Ormond Street Institute of Child Health, including GOSgene, an in-house gene sequencing facility that is helping researchers pinpoint the genes underpinning childhood disease. There will also be funding available to support individual researchers and students.
The funding also supports the NIHR Somers Clinical Research Facility which provides a dedicated space for children from across the UK who are taking part in clinical trials.
Research at the NIHR GOSH BRC will focus on four core themes that will build on previous work to understand the underlying causes of rare childhood diseases and find new drug-based and surgical treatments. A new theme for 2017-2022 is Advanced Treatments for Malformations and Tissue Damage, which will pioneer advanced technologies such as regenerative medicine to provide more treatment options for children born with birth defects or with malformations that develop early in childhood.
“We need to fully understand the molecular causes of the rare diseases we hope to treat”, said Professor Voit “This will be indispensable for starting new trials and offering new treatments.”
“The inspiration for developing new therapies is in the bloodstream at GOSH” he added. “The combination of pioneering researchers, excellent research facilities and NIHR support provides us with all the raw materials for us to continue to innovate in children’s medicine.”
Meet the BRC
On 17 May 2017 the NIHR GOSH BRC is holding a symposium to celebrate the launch of the new funding term. Register your interest to learn more about the world-leading research taking place at the GOSH BRC.
Gene therapy offers potential to extend lives of children with rare immune disorder
Children have had their lives changed by a ground-breaking gene therapy treatment at Great Ormond Street Hospital for a rare immunodeficiency.
Cutting-edge genomic technology saves girl from rare brain infection
Great Ormond Street Hospital has launched the UK’s first accredited ‘metagenomics’ testing service, that allows clinicians to identify infections that are otherwise undetectable.
New research analyses key immune cell
A new study led by researchers at University College London Great Ormond Street Institute of Child Health has found that women have a higher proportion of key immune cells between puberty and menopause.
First patient treated with groundbreaking gene therapy trial
A baby boy born with a rare condition has become the first in the world to be treated with a new, potentially lifechanging, investigational gene therapy on a clinical trial at Great Ormond Street Hospital (GOSH).